Does controlled-release metoprolol improve survival and reduce hospitalizations in patients with symptomatic heart failure?
Controlled-release metoprolol provides significant clinical benefits, including improved survival and reduced hospitalizations, in patients with symptomatic heart failure.
In this study of patients with symptomatic heartfailure, metoprolol CR/XL improved survival, reduced the need for hospitalizations due to worsening heart failure, improved NYHA functional class, and had beneficial effects on patient well-being.
Hjalmarson et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: